Bora Biologics Unveils $30 Million Expansion to Boost Drug Manufacturing Capacity
San Diego, Monday, 26 January 2026.
This $30 million upgrade introduces critical 2,000-liter scale bioreactors, significantly enhancing San Diego’s ability to produce life-saving biologics as demand for scalable manufacturing surges.
Strategic Infrastructure Investment
The official ribbon-cutting ceremony, held on January 26, 2026, marked the culmination of this significant capital project aimed at fortifying the company’s footprint in the United States [1][3]. By integrating between two and four 2,000-liter bioreactors, Bora Biologics has effectively bridged the critical gap between clinical development and commercial-scale production [1][4]. This expansion is not merely about adding volume; it represents a calculated enhancement of the facility’s upstream and downstream Good Manufacturing Practice (GMP) processing capabilities, designed to handle the complex requirements of single-use biologics manufacturing [1][2].
Regional Economic Impact
The operational upgrade allows the Contract Development and Manufacturing Organization (CDMO) to offer comprehensive end-to-end solutions, leveraging a track record that already includes over 100 successful cGMP manufacturing batches [1][4]. John R. Mosack, General Manager and Vice President of Operations for the San Diego site, noted that the expansion provides customers with both the commercial capacity and the specific expertise required to purify these sophisticated biological products [1][4].